GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,436.80
+24.60 (+1.74%)
At close: 4:36PM BST
Stock chart is not supported by your current browser
Previous Close1,412.20
Open1,401.60
Bid1,415.00 x 175400
Ask1,450.00 x 417900
Day's Range1,401.40 - 1,436.80
52 Week Range1,236.40 - 1,724.50
Volume8,498,186
Avg. Volume10,675,693
Market Cap70.294B
Beta1.03
PE Ratio (TTM)46.35
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.80 (5.63%)
Ex-Dividend Date2018-02-22
1y Target EstN/A
  • Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
    Zacks4 hours ago

    Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

    Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

  • Thomson Reuters StreetEvents19 hours ago

    Edited Transcript of GSK.L earnings conference call or presentation 25-Apr-18 1:00pm GMT

    Q1 2018 GlaxoSmithKline PLC Earnings Call

  • Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag
    Investor's Business Dailyyesterday

    Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag

    Shingrix sales were strong in the first quarter, GlaxoSmithKline said, though shares dipped on the company's broader revenue and profit lag.

  • Associated Pressyesterday

    Stronger pound weighs on revenues at drugmaker GSK

    LONDON (AP) — Pharmaceutical and consumer goods maker GlaxoSmithKline says first-quarter revenue dropped 2 percent as a stronger pound offset encouraging sales of a new shingles treatment.

  • Currency and pricing squeeze GSK as new shingles vaccine shines
    Reutersyesterday

    Currency and pricing squeeze GSK as new shingles vaccine shines

    GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. The vaccine, a rival to Merck & Co's older and less effective Zostavax, is a top priority for Chief Executive Emma Walmsley as she strives to improve GSK's drugs portfolio. Walmsley told reporters the Shingrix number was "very encouraging", although she noted that some of the revenue represented supplying necessary stock into the market.

  • GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss
    InvestorPlaceyesterday

    GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss

    GlaxoSmithKline plc (ADR) (NYSE:GSK) stock was down on Wednesday following an earnings miss for the first quarter of 2018.Source: Mike Mozart via Flickr (Modified)

  • Associated Pressyesterday

    Glaxo: 1Q Earnings Snapshot

    The Brentford Middlesex, Britain-based company said it had profit of 31 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to 68 cents per share. The results fell ...

  • Reutersyesterday

    Currency and pricing squeeze GSK as new shingles vaccine shines

    GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. The vaccine, a rival to Merck & Co's older and less effective Zostavax, is a top priority for Chief Executive Emma Walmsley as she strives to improve GSK's drugs portfolio. Walmsley told reporters the Shingrix number was "very encouraging", although she noted that some of the revenue represented supplying necessary stock into the market.

  • Glaxo (GSK) Misses on both Earnings and Revenue in Q1
    Zacksyesterday

    Glaxo (GSK) Misses on both Earnings and Revenue in Q1

    Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

  • Reutersyesterday

    GSK rules out entering Shire takeover battle

    LONDON (Reuters) - GlaxoSmithKline's (GSK.L) chief executive said on Wednesday she had no interest in acquiring Shire (SHP.L), the London-listed rare diseases specialist that Takeda Pharmaceutical hopes ...

  • Financial Timesyesterday

    [$$] Stronger pound weighs on GlaxoSmithKline revenues

    GlaxoSmithKline delivered sales of £7.2bn in the first quarter of this year but faced pressures due to the strengthening of the pound against the dollar. Revenues were in line with market expectations ...

  • Reutersyesterday

    Currency weighs on GlaxoSmithKline Q1 sales and earnings

    Drugmaker GlaxoSmithKline reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles vaccine Shingrix. GSK's ...

  • Financial Times2 days ago

    [$$] The London Report: Metro dives on capital ratio worries

    hit a six-month low after results from the lender showed a continued weakening of its capital ratios, which raised fears of a cash call by the year end. “We think management would be well advised to act ahead of its current stated plan of not raising fresh equity capital until 2019,” said Investec. led industrial stocks lower after Caterpillar said in a post-results conference call that the first quarter will probably be this year’s high water mark.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks6 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Reuters6 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO (Reuters) - Procter & Gamble's (PG.N) $4.2 billion deal for Merck's (MRCG.DE) vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.

  • Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
    Motley Fool6 days ago

    Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

    Which stock wins in a head-to-head matchup of these two big pharma companies?

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks7 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Novartis CEO feels heat on U.S. generics, Cosentyx drop
    Reuters7 days ago

    Novartis CEO feels heat on U.S. generics, Cosentyx drop

    Swiss drugmaker Novartis' (NOVN.S) first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.

  • Reuters7 days ago

    AI drug hunter BenevolentAI worth $2 billion after fund raising

    The aim is to use modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests. AI systems already play a central role in other high-tech sectors such as the development of driverless cars and facial recognition software.

  • Reuters8 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.

  • Reuters8 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis, and it showed benefits over other treatments in the study.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Industry fears disruption as EU excludes UK from drug approvals
    Reuters8 days ago

    Industry fears disruption as EU excludes UK from drug approvals

    A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients. The move confounds hopes for continued joint cooperation via the European Medicines Agency (EMA), at least during a transition or implementation period until the end of 2020 when the UK will remain closely tied to the European Union. Prime Minister Theresa May said in a speech on March 2 that London wanted to explore ways to keep Britain a part of EU agencies, such as the EMA.

  • Reuters8 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...